{"protocolSection":{"identificationModule":{"nctId":"NCT05397405","orgStudyIdInfo":{"id":"sICASBLM"},"organization":{"fullName":"Nanjing First Hospital, Nanjing Medical University","class":"OTHER"},"briefTitle":"Improving Blood Lipid Management in Symptomatic Intracranial Atherosclerotic Stenosis on Clinical Outcome","officialTitle":"A Prospective Observational Study on the Effect of Improving Blood Lipid Management on the Clinical Prognosis of Symptomatic Intracranial Atherosclerotic Stenosis（sICASBLM）","acronym":"sICASBLM"},"statusModule":{"statusVerifiedDate":"2023-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-05-23","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-05-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-05-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-05-23","studyFirstSubmitQcDate":"2022-05-26","studyFirstPostDateStruct":{"date":"2022-05-31","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-07-21","lastUpdatePostDateStruct":{"date":"2023-07-24","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Nanjing First Hospital, Nanjing Medical University","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\\>1.8mmol/L) without endovascular therapy.","detailedDescription":"sICASBLM aims to determine the effectiveness of conventional lipid management combined with PCSK9 inhibitors compared to conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg) in reducing the incidence of recurrent stroke in patients with moderate to severe symptomatic intracranial atherosclerotic stenosis (LDL-C\\>1.8mmol/L) without endovascular therapy."},"conditionsModule":{"conditions":["Intracranial Artery Stenosis"],"keywords":["symptomatic intracranial atherosclerotic stenosis","stroke","blood lipid management","PCSK9 inhibitors"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":180,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intervention group","type":"EXPERIMENTAL","description":"Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months","interventionNames":["Drug: PCSK9 inhibitor"]},{"label":"Control group","type":"NO_INTERVENTION","description":"Blood Lipid management with atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg for 6-12 months"}],"interventions":[{"type":"DRUG","name":"PCSK9 inhibitor","description":"The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months","armGroupLabels":["Intervention group"],"otherNames":["intensive blood lipid lowing"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Recurrent stroke","description":"the recurrent rate of clinical stroke","timeFrame":"6 months-12 months"}],"secondaryOutcomes":[{"measure":"Intracranial arterial","description":"Degree of change in intracranial arterial stenosis","timeFrame":"6 months or 12 months"},{"measure":"Plaque changes","description":"Plaque volume and load changes","timeFrame":"6 months or 12 months"},{"measure":"Vascular remodeling index","description":"Vascular remodeling index changes","timeFrame":"6 months or 12 months"},{"measure":"Adverse events","description":"The incidence of muscle related events, allergic reactions, injection site reactions, bleeding events and other adverse events was assessed","timeFrame":"6 months or 12 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years\n2. Symptomatic intracranial atherosclerotic stenosis of moderate to severe, did not receive intravenous thrombolysis, thrombectomy, stent implantation and other intravascular treatment\n3. low density lipoprotein cholesterol \\> 70mg/dl (1.8mmol/L)\n4. Receive 3T magnetic resonance angiography or multi-mode MR (high resolution is required), angiography can be included, and images for analysis can be obtained.\n5. Lipid-lowering indications of statins\n6. Signed an approved informed consents\n\nExclusion Criteria:\n\n1. Contraindications to statins\n2. There are contraindications to MRI examination or cannot accept MRI examination\n3. Stenosis caused by vasculitis, arterial dissection and moyamoya disease\n4. Patients with active bleeding or obvious bleeding tendency\n5. Severe heart, lung, renal insufficiency, malignant tumor or other malignant diseases, and death is highly likely within 7 days; pregnancy or women who are lactating\n6. Uncontrolled severe diabetes and hypertension\n7. Other conditions inappropriate for inclusion judged by investigators","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Junshan Zhou","role":"CONTACT","phone":"8602587726218","email":"zhjsh333@126.com"},{"name":"Qiwen Deng","role":"CONTACT","phone":"8602587726218","email":"qiw_deng@163.com"}],"locations":[{"facility":"Nanjing First Hospital, Nanjing Medical University","status":"RECRUITING","city":"Nanjing","state":"Jiangsu","zip":"210006","country":"China","contacts":[{"name":"Junshan Zhou, M.D.","role":"CONTACT","phone":"+86025-87726218","email":"zhjsh333@126.com"},{"name":"Qiwen Deng, M.D.","role":"CONTACT","phone":"+86025-87726218","email":"qiw_deng@163.com"}],"geoPoint":{"lat":32.06167,"lon":118.77778}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000003251","term":"Constriction, Pathologic"}],"ancestors":[{"id":"D000020763","term":"Pathological Conditions, Anatomical"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M6165","name":"Constriction, Pathologic","asFound":"Stenosis","relevance":"HIGH"},{"id":"M22209","name":"Pathological Conditions, Anatomical","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000091362","term":"PCSK9 Inhibitors"}],"ancestors":[{"id":"D000000924","term":"Anticholesteremic Agents"},{"id":"D000000960","term":"Hypolipidemic Agents"},{"id":"D000000963","term":"Antimetabolites"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000057847","term":"Lipid Regulating Agents"}],"browseLeaves":[{"id":"M351","name":"Atorvastatin","relevance":"LOW"},{"id":"M298","name":"Rosuvastatin Calcium","relevance":"LOW"},{"id":"M21403","name":"Simvastatin","relevance":"LOW"},{"id":"M2850","name":"PCSK9 Inhibitors","asFound":"Antigen-Specific","relevance":"HIGH"},{"id":"M3933","name":"Anticholesteremic Agents","relevance":"LOW"},{"id":"M3968","name":"Hypolipidemic Agents","relevance":"LOW"},{"id":"M3971","name":"Antimetabolites","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"M28573","name":"Lipid Regulating Agents","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"Lipd","name":"Lipid Regulating Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}